Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 70.60M P/E - EPS this Y 11.50% Ern Qtrly Grth -
Income -54.19M Forward P/E -1.45 EPS next Y 4.00% 50D Avg Chg -19.00%
Sales 3.5M PEG - EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 3.06 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.70 Quick Ratio 4.07 Shares Outstanding 27.36M 52W Low Chg 46.00%
Insider Own 4.94% ROA -46.99% Shares Float 19.08M Beta 1.48
Inst Own 59.94% ROE -260.60% Shares Shorted/Prior 2.06M/1.70M Price 3.20
Gross Margin 23.14% Profit Margin - Avg. Volume 178,604 Target Price 20.50
Oper. Margin -1,377.14% Earnings Date May 9 Volume 108,439 Change -3.32%
About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc. News
04/25/24 ABEO: Receives CRL Based on Need for More CMC Information…
04/23/24 FDA rejects Abeona cell therapy, asks for more manufacturing data
04/22/24 Abeona Therapeutics Provides Regulatory Update on Pz-cel
04/01/24 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01:00 PM Here's Why We're Not Too Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation
03/19/24 Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results
03/18/24 Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
03/10/24 Several Insiders Invested In Abeona Therapeutics Flagging Positive News
02/15/24 Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc
02/12/24 Individual investors in Abeona Therapeutics Inc. (NASDAQ:ABEO) are its biggest bettors, and their bets paid off as stock gained 45% last week
02/01/24 ABEO: FDA BIMO Inspection and BLA Mid-Cycle Review Complete…
02/01/24 Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
01/16/24 Abeona Therapeutics Inc. (NASDAQ:ABEO): When Will It Breakeven?
01/08/24 Abeona Therapeutics Announces $50 Million Credit Facility
12/23/23 Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%
11/29/23 ABEO: BLA for Pz-Cel (EB-101) Accepted with Priority Review; PDUFA Date of May 25, 2024…
11/27/23 Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
11/17/23 Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript
11/15/23 ABEO: BLA Submitted for Pz-Cel (EB-101); Increasing Valuation to $11.00…
11/14/23 Q3 2023 Abeona Therapeutics Inc Earnings Call
ABEO Chatroom

User Image TheStockSinatra Posted - 7 hours ago

$ABEO 3.10 a Juicy average for this one. Load up for the bounce imo. She is a prime bottom looking for a ride up soon.

User Image Steve_TheBull_Rogers Posted - 7 hours ago

$ABEO I would wait until after earnings in just 2 weeks to add here The CRL and resub expenditure will be added & algos will drop here No meeting with FDA & resub until q3 with a q1 2025 fda date approx

User Image PLATINUM_TRADES Posted - 8 hours ago

$ABEO bounce time with $3.50 next leg up beaten down time for a big bounce here🥊🥊🥊🥊

User Image kenny91655 Posted - 11 hours ago

$ABEO Some things never change On 7/25/19, Abeona announced a delay in the start of the pivotal EB-101 clinical trial following interactions with FDA, where a number of manufacturing-related issues were raised. We see this as a negative development for the company with potential implications to other pipeline indications given the crucial importance of manufacturing in gene therapy. We also take a more cautious view of the MPS III programs, where there has not been material progress on enrollment and we believe more time may be needed to determine potential clinical benefits of gene therapy in this patient population. Downgrade to Neutral, reduce PT to $4.

User Image Weber369 Posted - 12 hours ago

$ABEO 10000 STK zu 3,02 € gekauft,Gruss aus Deutschland

User Image Steve_TheBull_Rogers Posted - 13 hours ago

$ABEO Bottom is forming on this one

User Image R_NW Posted - 13 hours ago

$ABEO This is my only bio that ended green for the day. I call that a win.

User Image Viinamitta Posted - 14 hours ago

$ABEO ”resources to fund operations into the first quarter of 2025 before accounting for any revenue from commercial sales of pz-cel” ”Anticipates completing and submitting requested CMC information in 3Q 2024” ”Research and development expenses for the full year ended December 31, 2023 were $31.1 million - - General and administrative expenses were $19.0 million for the full year ended December 31, 2023” To become profitable with those expenses they’d need 10% of peak sales (500M) which seems reasonable, right? Regardless, after the resubmit, it’s going to take a while to get the approval. After that they will need more money to ramp up commercialization than just to cover current operations. So if we assume it’s going to be approved next round they still need more money this year. 100M dilution from this level would result in 60M shares, which 5 x peak sales gives about $40 per share. What did I miss? Not accounting anything for the rest of the pipeline. Is the management bunch of cunts?

User Image MSBio Posted - 16 hours ago

$ABEO a safe double in the coming months

User Image Rollercoaster22 Posted - 16 hours ago

$ABEO The only ticker in my portfolio that gives me that bullish feeling right now.

User Image MSBio Posted - 16 hours ago

$ABEO not bad, a little bit green in a red sea

User Image PPT_for_me Posted - 17 hours ago

$ABEO

User Image IAmSureGoingUp Posted - 17 hours ago

$ABEO Plenty of cash; 50M+, NO long term debt and access to a term loan. Low float and 500M block buster skin product that the FDA will approve soon (5-9 months). In the dumps because the FDA needed more info on manufacturing and labeling. Nothing is wrong the product or the phase III trial.

User Image ccledez Posted - 17 hours ago

$ABEO got some at 3.14

User Image Tjcmd Posted - 17 hours ago

$ABEO cash runway?

User Image IAmSureGoingUp Posted - 17 hours ago

$ABEO Looks like the 3 day rule is kicking in. Buying volume is picking up a bit.

User Image DollarDan1 Posted - 17 hours ago

@PPT_for_me $ABEO Wish granted!

User Image osvalles Posted - 17 hours ago

$AKBA $OCGN $ABEO $MCRB $IBRX

User Image jacksparo Posted - 18 hours ago

$MCRB $IBRX $ABEO $OCGN $AKBA Values hold in red market zone! Holding strong throw the 3rd quarter of 2024 . There will be a good patience to pay off there 📈! I will keep posting the valuable stuff and ignore the childish ✅!

User Image debbiekatz Posted - 19 hours ago

$abeo 3.16 or lower

User Image Rollercoaster22 Posted - 19 hours ago

$ABEO Wants to go north.

User Image lionheart_007 Posted - 19 hours ago

$ABEO was this really a 100+ stock in 2019, and why did it fall so hard?

User Image PPT_for_me Posted - 19 hours ago

$ABEO A little green day with this down market would be a welcome sign

User Image ccledez Posted - 19 hours ago

$ABEO fell asleep on a buy Can I get in at 3.05? Or too cheap... Let's see

User Image Robfelinv Posted - 19 hours ago

$ABEO added..looks good time to do it

User Image Jimmy1940 Posted - 20 hours ago

$ABEO In @ 3,18

User Image SalmanAziz Posted - 20 hours ago

$ABEO warming up for a reversal

User Image trillontusk Posted - 20 hours ago

$ABEO A reversal in sight.

User Image TheMyth2020 Posted - 20 hours ago

$ABEO When a company gets a CRL and there is wrong with the drug, how long until a new PDFUA date does it usually take, during the covid date they used to push the date 3 months, if there is no issues with the drug just paper work issues why not just push it down 3 months?

User Image OneTime4386 Posted - 20 hours ago

$ABEO losers average losers

Analyst Ratings
Cantor Fitzgerald Overweight Apr 23, 24
Cantor Fitzgerald Overweight Aug 24, 23
Cantor Fitzgerald Overweight Jul 13, 23
Alliance Global Partners Buy May 24, 23
SVB Leerink Market Perform Nov 14, 22
Cantor Fitzgerald Overweight Nov 8, 22
SVB Leerink Market Perform Aug 11, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Alvino Mark Director Director Sep 27 Sell 3.9145 6,316 24,724 69,900 09/29/23
Charles Faith L. Director Director Sep 27 Sell 4.9128 8,330 40,924 70,773 09/29/23
Alland Leila Director Director Sep 27 Sell 3.9014 7,246 28,270 71,857 09/29/23
Amoroso Michael Director Director Sep 27 Sell 3.9111 5,508 21,542 108,957 09/29/23
Seshadri Vishwas Chief Executive Offi.. Chief Executive Officer Sep 27 Buy 4.07 20,000 81,400 521,731 09/29/23
Vazzano Joseph Walter Chief Financial Offi.. Chief Financial Officer Sep 19 Buy 3.76 3,000 11,280 238,179 09/20/23
O'Malley Brendan M. SVP, General Counsel SVP, General Counsel Sep 18 Buy 3.80 3,000 11,400 187,421 09/19/23
Amoroso Michael Director Director Mar 20 Sell 2.33 268 624 56,441 03/21/23
Vazzano Joseph Walter Chief Financial Offi.. Chief Financial Officer Nov 18 Buy 4.00 2,500 10,000 95,250 11/21/22
O'Malley Brendan M. SVP, General Counsel SVP, General Counsel Nov 18 Buy 3.99 7,500 29,925 87,961 11/21/22
O'Malley Brendan M. SVP, General Counsel SVP, General Counsel Oct 05 Sell 1.05 25,210 26,470 248,244 10/08/21
- - - Jan 19 Sell 2.03 320,000 649,600 11,599,292 01/19/21
Mann Paul Elliot Director Director Jan 05 Sell 1.54 30,488 46,952 132,664 01/05/21